26 Aug. 2025

ANVISA’s GMP Certification Granted to Adimmune Significantly Advances the Progress toward Regulatory Approval in Brazil

Adimmune Corporation (4142) today announced that its Tanzi plant in Taichung has officially received Good Manufacturing Practice (GMP) certification from the Brazilian Health Regulatory Agency (ANVISA). The certification follows an on-site inspection conducted in June, during which ANVISA officials reviewed Adimmune’s influenza vaccine production process.

08 Aug. 2025

Adimmune Enhances Technical Capabilities and Expands CDMO Capacity

Adimmune Corporation (4142) announced today at its investor conference that the company has implemented operational adjustments in response to shifting global political and economic circumstances. In the first half of this year, Adimmune successfully passed inspections by Brazilian ANVISA and EMA respectively. To meet growing demand from clients for additional production capacity, the company’s existing facilities are operating at full load. Adimmune has therefore initiated the installation of a third automated aseptic filling line with an annual capacity of 4 million doses, designed to serve customized, small-batch, and high-value products, and provide end-to-end services from clinical trials to commercial manufacturing—enhancing both capacity and scheduling flexibility.

09 Jul. 2025

Adimmune Adopts QbD to Enhance Process and Product Development

Adimmune Corporation (TWSE: 4142) has been adopting Quality by Design (QbD) practices to align with international standards, enhance its capabilities in process and product development, support international CDMO (contract development and manufacturing organization) projects, and drive new business and technology expansion.

03 Jul. 2024

Enimmune's Enterovirus 71 Vaccine Demonstrates 99.21% Efficacy in Phase III Clinical Trial

Enimmune Corp. (TWSE: 6564), a subsidiary of Adimmune Corporation, today announced the unblinding results of its phase III clinical trial for EnVAX-A71, Enimmune’s enterovirus 71 (EV71) vaccine. The trial demonstrated an impressive vaccine efficacy of 99.21%, establishing EnVAX-A71 as the most effective EV71 vaccine currently available worldwide.

14 May. 2024

Adimmune Signs SMTA2 with WHO

Adimmune Corporation (TWSE: 4142) announced that, following years of negotiation, Adimmune and World Health Organization (WHO) have concluded the SMTA2 (Standard Material Transfer Agreement 2) under the Pandemic Influenza Preparedness (PIP) Framework. The SMTA2 ensures that, in the event of an influenza pandemic, the partner influenza vaccine manufacturers or pharmaceutical companies can access the virus strains from WHO to promptly develop the pandemic influenza vaccine or antiviral drugs in response. In exchange, Adimmune is obligated to donate and reserve a percentage of its newly developed pandemic influenza vaccines production for WHO to address the global pandemic and fulfill Adimmune’s commitments and obligations under the SMTA2.

26 Dec. 2023

Adimmune Broadens Market Reach for Flu Vaccine, Initiates New CDMO Ventures in 2024

Adimmune Corporation (TWSE: 4142) announced during the institutional investor conference today that Adimmune has submitted the application for marketing authorization of its quadrivalent influenza vaccine to Brazilian ANVISA in November, marking its official initiation for entry into the Southern Hemisphere’s influenza market. Another significant development is that Adimmune has successfully resumed production of its tetanus vaccine in Taiwan, and the supply has generated positive reception in the domestic market. The demand of tetanus vaccine is also strong in Southeast Asia and China, and Adimmune may anticipate a promising leap in export sales once the tetanus vaccine is approved in those markets. Building on its current CDMO performance, Adimmune foresees expanding partnership with bio-pharmaceutical manufacturers in Korea and France and expects to realize substantial growth in 2024.

24 Oct. 2023

Adimmune’s Tetanus Vaccine Set to Re-launce by Year’s End

Adimmune Corporation (TWSE: 4142) today announced that the Company has successfully extended the marketing authorization for its tetanus vaccine and is prepared to commence the steady supply of no less than one million doses annually for the domestic market in Taiwan as early as November 2023.

23 Aug. 2023

Epidemic Prevention in Taiwan: Adimmune Secures Advanced Purchase Agreement for Pandemic Influenza Vaccine

Adimmune Corporation (TWSE: 4142) today announced the Company has been awarded the advanced purchase agreement (APA) for pandemic influenza vaccine by Taiwan Centers for Disease Control (CDC), Ministry of Health and Welfare. This APA ensures Taiwan’s swift access to vaccines in the event of a new influenza pandemic. As the only vaccine manufacturer in Taiwan participating in the Influenza Vaccine Supply (IVS) International Task Force of the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Adimmune is uniquely positioned to obtain new influenza virus strains promptly.

18 Jul. 2023

Adimmune’s Production Line Receives EMA GMP Certification, Advancing International CDMO Opportunities

Adimmune (TWSE: 4142) announced today that both the first and second automated filling and packaging lines have successfully passed the European Medicines Agency’s (EMA) on-site GMP inspection and received the certification. This marks the fifth time in the past ten years that Adimmune has obtained the EMA GMP certification, further positioning the company for global CDMO opportunities.

06 Feb. 2023

Enimmune EnVAX-A71 Is Exploring ASEAN Market, Adimmune Achieves Sustainable Growth

EnVAX-A71, the first Taiwan locally developed and manufactured vaccine against enterovirus 71, has received the Market Authorization from TFDA. Collaboration to explore the ASEAN market through clinical trials is being discussed with potential partners

29 Jan. 2023

Adimmune’s Subsidiary Enimmune Receives EV71 Vaccine Marketing Authorization, First Taiwan Developed and Manufactured Vaccine

Taiwan Food and Drug Administration granted the Marketing Authorization for EnVAX-A71, the first Taiwan independently developed and manufactured vaccine to prevent EV71

30 Nov. 2022

Adimmune Completes Process Development with SCD for Biosimilar

Adimmune Corporation announced the completion of the process development with SCD for the biosimilar to Eylea, a novel intravitreal injection solution for macular degeneration

News